Long-term MRI outcomes of the phase III RAPID-axSpA study demonstrate that early improvements in spinal and sacroiliac joint inflammation achieved following treatment with certolizumab are maintained to week 204, with similar responses in patients with ankylosing spondylitis and those with non-radiographic axial spondyloarthritis. Assessment of sacroiliac joint radiographs showed limited overall progression over 4 years, with most progression observed during years 0–2 as compared with years 2–4 of the study.
References
van der Heijde, D. et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212377 (2018)
Rights and permissions
About this article
Cite this article
Onuora, S. Effects of certolizumab pegol sustained at 4 years. Nat Rev Rheumatol 14, 122 (2018). https://doi.org/10.1038/nrrheum.2018.20
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2018.20
